

# Katherine J. Aitchison

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2925279/publications.pdf>

Version: 2024-02-01

178  
papers

9,873  
citations

26630

56  
h-index

40979

93  
g-index

202  
all docs

202  
docs citations

202  
times ranked

11794  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2022, 2, 115-126.	2.2	31
2	CYP2D6 and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2021, 31, 33-45.	1.3	15
3	Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 185-194.	1.9	7
4	Mobile App-Based Self-Report Questionnaires for the Assessment and Monitoring of Bipolar Disorder: Systematic Review. <i>JMIR Formative Research</i> , 2021, 5, e13770.	1.4	9
5	Sequence2Script: A Web-Based Tool for Translation of Pharmacogenetic Data Into Evidence-Based Prescribing Recommendations. <i>Frontiers in Pharmacology</i> , 2021, 12, 636650.	3.5	22
6	Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds. <i>Frontiers in Pharmacology</i> , 2021, 12, 713178.	3.5	2
7	Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials. <i>Journal of Psychiatric Research</i> , 2021, 140, 267-281.	3.1	22
8	Internal consistency and concurrent validity of self-report components of a new instrument for the assessment of suicidality, the Suicide Ideation and Behavior Assessment Tool (SIBAT). <i>Psychiatry Research</i> , 2021, 304, 114128.	3.3	1
9	Review and Consensus on Pharmacogenomic Testing in Psychiatry. <i>Pharmacopsychiatry</i> , 2021, 54, 5-17.	3.3	96
10	Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 29-39.	1.5	8
11	The feasibility and acceptability of mobile application-based assessment of suicidality using self-report components of a novel tool, the Suicide Ideation and Behavior Assessment Tool (SIBAT). <i>Psychiatry Research</i> , 2021, 307, 114316.	3.3	1
12	Methodology for clinical genotyping of CYP2D6 and CYP2C19. <i>Translational Psychiatry</i> , 2021, 11, 596.	4.8	15
13	Dimensions of temperament and character as predictors of antidepressant discontinuation, response and adverse reactions during treatment with nortriptyline and escitalopram. <i>Psychological Medicine</i> , 2021, , 1-9.	4.5	3
14	Decreased Medial Prefrontal Cortex Glutamate Levels in Perimenopausal Women. <i>Frontiers in Psychiatry</i> , 2021, 12, 763562.	2.6	6
15	A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression. <i>Molecular Psychiatry</i> , 2020, 25, 1312-1322.	7.9	20
16	Reply to Dawes et al.. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 586-587.	1.9	0
17	Pharmacogenomics and Psychopharmacology. , 2020, , 151-202.		2
18	Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 521-530.	1.9	32

#	ARTICLE	IF	CITATIONS
19	Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. <i>Frontiers in Psychiatry</i> , 2020, 11, 94.	2.6	74
20	How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. <i>Frontiers in Genetics</i> , 2020, 11, 491895.	2.3	28
21	T75GWAS AND PATHWAY ENRICHMENT ANALYSIS IN ADVERSE DRUG REACTIONS IN DEPRESSION. <i>European Neuropsychopharmacology</i> , 2019, 29, S255-S256.	0.7	0
22	Trend level gene-gender interaction effect for the BDNF rs6265 variant on age of onset of psychosis. <i>Psychiatry Research</i> , 2019, 280, 112500.	3.3	5
23	F93. CYP2D6 Revisited in GENDEP, a Multicenter Clinical Trial of Nortriptyline and Escitalopram. <i>Biological Psychiatry</i> , 2019, 85, S248-S249.	1.3	0
24	Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. <i>British Journal of Psychiatry</i> , 2019, 215, 494-501.	2.8	10
25	Differential gene expression analysis in blood of first episode psychosis patients. <i>Schizophrenia Research</i> , 2019, 209, 88-97.	2.0	27
26	Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	2.2	7
27	Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma. <i>Frontiers in Psychiatry</i> , 2019, 10, 808.	2.6	133
28	Prediction and Understanding of Resilience in Albertan Families: Longitudinal Study of Disaster Responses (PURLS) â€“ Protocol. <i>Frontiers in Psychiatry</i> , 2019, 10, 729.	2.6	3
29	Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. <i>Scientific Reports</i> , 2018, 8, 5530.	3.3	51
30	Implications of Cannabis Legalization on Youth and Young Adults. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 65-71.	1.9	17
31	New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. <i>Pharmacogenomics Journal</i> , 2018, 18, 413-421.	2.0	40
32	Contribution of genes in the GABAergic pathway to bipolar disorder and its executive function deficit in the Chinese Han population. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 50-67.	1.7	4
33	Associations between the <b><i>LEP</i></b>; -2548G/A Promoter and Baseline Weight and between <b><i>LEPR</i></b>; Gln223Arg and Lys656Asn Variants and Change in BMI <b><i>z</i></b>; Scores in Arab Children and Adolescents Treated with Risperidone. <i>Molecular Neuropsychiatry</i> . 2018. 4. 111-117.	2.9	5
34	F190. EFFECT OF SELECTED GENE VARIANTS ON THE RELATIONSHIP BETWEEN EARLY CANNABIS USE AND AGE OF ONSET OF PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S295-S295.	4.3	0
35	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. <i>European Neuropsychopharmacology</i> , 2018, 28, 945-954.	0.7	64
36	Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). <i>Translational Psychiatry</i> , 2018, 8, 150.	4.8	19

#	ARTICLE	IF	CITATIONS
37	Genetic disposition to inflammation and response to antidepressants in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2018, 105, 17-22.	3.1	18
38	Pharmacogenetics of antidepressant response: A polygenic approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 75, 128-134.	4.8	71
39	Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 344-350.	4.1	202
40	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. <i>Nature Communications</i> , 2017, 8, 15497.	12.8	144
41	Investigation of the <i>COMT</i> Val158Met variant association with age of onset of psychosis, adjusting for cannabis use. <i>Brain and Behavior</i> , 2017, 7, e00850.	2.2	14
42	Interaction between the <i>FTO</i> gene, body mass index and depression: meta-analysis of 13701 individuals. <i>British Journal of Psychiatry</i> , 2017, 211, 70-76.	2.8	49
43	An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis. <i>Biological Psychiatry</i> , 2017, 81, 470-477.	1.3	176
44	Meta-analysis of CYP2C19 association with efficacy and side effects of citalopram and escitalopram. <i>European Neuropsychopharmacology</i> , 2017, 27, S582-S583.	0.7	0
45	Interplay between Schizophrenia Polygenic Risk Score and Childhood Adversity in First-Presentation Psychotic Disorder: A Pilot Study. <i>PLoS ONE</i> , 2016, 11, e0163319.	2.5	52
46	Combining clinical variables to optimize prediction of antidepressant treatment outcomes. <i>Journal of Psychiatric Research</i> , 2016, 78, 94-102.	3.1	149
47	Transcriptomics and the mechanisms of antidepressant efficacy. <i>European Neuropsychopharmacology</i> , 2016, 26, 105-112.	0.7	19
48	Changes in biomarkers of bone turnover in an aripiprazole add-on or switching study. <i>Schizophrenia Research</i> , 2016, 170, 245-251.	2.0	6
49	Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder. <i>Biological Psychiatry</i> , 2016, 79, 329-336.	1.3	21
50	Familiality and SNP heritability of age at onset and episodicity in major depressive disorder. <i>Psychological Medicine</i> , 2015, 45, 2215-2225.	4.5	21
51	Exploring the role of drug-metabolising enzymes in antidepressant side effects. <i>Psychopharmacology</i> , 2015, 232, 2609-2617.	3.1	31
52	Modulatory effects of brain-derived neurotrophic factor Val66Met polymorphism on prefrontal regions in major depressive disorder. <i>British Journal of Psychiatry</i> , 2015, 206, 379-384.	2.8	56
53	Authors' reply. <i>British Journal of Psychiatry</i> , 2015, 207, 363-364.	2.8	1
54	Role of a Combination of Seven Micronutrients in the Management of Glioblastoma Multiforme. <i>Clinical Oncology</i> , 2015, 27, 370-371.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. <i>Schizophrenia Bulletin</i> , 2015, 41, 1171-1182.	4.3	73
56	Neurological Structure Variations in Individuals with Autism Spectrum Disorder: a Review. <i>Journal of Microbiology and Biotechnology</i> , 2014, 24, 268-275.	2.1	3
57	Investigation of blood mRNA biomarkers for suicidality in an independent sample. <i>Translational Psychiatry</i> , 2014, 4, e474-e474.	4.8	24
58	The effect of age on DNA concentration from whole saliva: Implications for the standard isolation method. <i>American Journal of Human Biology</i> , 2014, 26, 859-862.	1.6	3
59	Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study. <i>Journal of Psychopharmacology</i> , 2014, 28, 142-150.	4.0	18
60	Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. <i>Journal of Psychopharmacology</i> , 2014, 28, 133-141.	4.0	75
61	Genomics for clinical utility: the future is near. <i>Genome Medicine</i> , 2014, 6, 3.	8.2	4
62	P.2.a.021 Genome-wide association study of antidepressant-induced sexual dysfunction in depressed males. <i>European Neuropsychopharmacology</i> , 2014, 24, S373-S374.	0.7	0
63	Association of tardive dyskinesia with variation in <i>CYP2D6</i> : Is there a role for active metabolites?. <i>Journal of Psychopharmacology</i> , 2014, 28, 665-670.	4.0	21
64	Association of KIBRA rs17070145 polymorphism with episodic memory in the early stages of a human neurodevelopmental disorder. <i>Psychiatry Research</i> , 2014, 220, 37-43.	3.3	12
65	Effects of antidepressant drug exposure on gene expression in the developing cerebral cortex. <i>Synapse</i> , 2014, 68, 209-220.	1.2	10
66	NPAS3 variants in schizophrenia: a neuroimaging study. <i>BMC Medical Genetics</i> , 2014, 15, 37.	2.1	1
67	Relationship between obesity and the risk of clinically significant depression: Mendelian randomisation study. <i>British Journal of Psychiatry</i> , 2014, 205, 24-28.	2.8	62
68	Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. <i>Schizophrenia Research</i> , 2014, 157, 84-89.	2.0	50
69	Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. <i>Pharmacogenomics Journal</i> , 2014, 14, 395-399.	2.0	20
70	Genome-wide association analysis of copy number variation in recurrent depressive disorder. <i>Molecular Psychiatry</i> , 2013, 18, 183-189.	7.9	45
71	Duration of untreated psychosis in adolescents: Ethnic differences and clinical profiles. <i>Schizophrenia Research</i> , 2013, 150, 526-532.	2.0	35
72	Benzodiazepines: Risks and benefits. A reconsideration. <i>Journal of Psychopharmacology</i> , 2013, 27, 967-971.	4.0	177

#	ARTICLE	IF	CITATIONS
73	Genome-wide association analysis accounting for environmental factors through propensity score matching: Application to stressful life events in major depressive disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 521-529.	1.7	16
74	Serum and gene expression profile of cytokines in first-episode psychosis. <i>Brain, Behavior, and Immunity</i> , 2013, 31, 90-95.	4.1	174
75	Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. <i>European Neuropsychopharmacology</i> , 2013, 23, 1105-1114.	0.7	68
76	P.4.002 Genetic differences in drug-metabolising enzymes: can they be used to predict antidepressant treatment response?. <i>European Neuropsychopharmacology</i> , 2013, 23, S69-S70.	0.7	0
77	Modulation of amygdala response and connectivity in depression by serotonin transporter polymorphism and diagnosis. <i>Journal of Affective Disorders</i> , 2013, 150, 96-103.	4.1	70
78	Weight Gain and Other Metabolic Adverse Effects Associated with Atypical Antipsychotic Treatment of Children and Adolescents: A Systematic Review and Meta-analysis. <i>Paediatric Drugs</i> , 2013, 15, 139-150.	3.1	122
79	Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies. <i>American Journal of Psychiatry</i> , 2013, 170, 207-217.	7.2	216
80	Reply to "MDMA can increase cortical levels by 800% in dance clubbers" Parrott et al.. <i>Journal of Psychopharmacology</i> , 2013, 27, 115-116.	4.0	4
81	Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline "Predictors" and Longitudinal "Targets". <i>Neuropsychopharmacology</i> , 2013, 38, 377-385.	5.4	372
82	Ecstasy, legal highs and designer drug use: A Canadian perspective. <i>Drug Science, Policy and Law</i> , 2013, 1, 205032451350919.	1.3	5
83	Ethnic variations in pathways into early intervention services for psychosis. <i>British Journal of Psychiatry</i> , 2013, 202, 277-283.	2.8	46
84	Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption. <i>Journal of Psychopharmacology</i> , 2012, 26, 419-428.	4.0	33
85	Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis. <i>PLoS Medicine</i> , 2012, 9, e1001326.	8.4	110
86	Can genetics inform the management of cognitive deficits in schizophrenia?. <i>Journal of Psychopharmacology</i> , 2012, 26, 334-348.	4.0	9
87	<i>CYP2C19</i> genotype predicts steady state escitalopram concentration in GENDEP. <i>Journal of Psychopharmacology</i> , 2012, 26, 398-407.	4.0	69
88	Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in <i>CYP2D6</i> and <i>COMT</i> . <i>Journal of Psychopharmacology</i> , 2012, 26, 408-418.	4.0	17
89	Special issue on Pharmacogenetics. <i>Journal of Psychopharmacology</i> , 2012, 26, 333-333.	4.0	0
90	Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. <i>Psychological Medicine</i> , 2012, 42, 967-980.	4.5	298

#	ARTICLE	IF	CITATIONS
91	P.2.c.028 Candidate genes expression profile associated with antidepressants response: baseline predictors and longitudinal targets. <i>European Neuropsychopharmacology</i> , 2012, 22, S266-S267.	0.7	0
92	Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. <i>Pharmacogenomics Journal</i> , 2012, 12, 68-77.	2.0	92
93	Dissecting the Genetic Heterogeneity of Depression Through Age at Onset. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2012, 159B, 859-868.	1.7	31
94	White matter abnormalities and illness severity in major depressive disorder. <i>British Journal of Psychiatry</i> , 2012, 201, 33-39.	2.8	126
95	Depressive disorder moderates the effect of the FTO gene on body mass index. <i>Molecular Psychiatry</i> , 2012, 17, 604-611.	7.9	72
96	Reduced Anxiety and Depression-Like Behaviours in the Circadian Period Mutant Mouse Afterhours. <i>PLoS ONE</i> , 2012, 7, e38263.	2.5	54
97	Convergent Animal and Human Evidence Suggests a Role of PPM1A Gene in Response to Antidepressants. <i>Biological Psychiatry</i> , 2011, 69, 360-365.	1.3	30
98	Genomewide Association Scan of Suicidal Thoughts and Behaviour in Major Depression. <i>PLoS ONE</i> , 2011, 6, e20690.	2.5	98
99	Antidepressants and the resilience to early-life stress in inbred mouse strains. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 779-789.	1.5	28
100	Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. <i>Journal of Affective Disorders</i> , 2011, 132, 112-120.	4.1	93
101	Changes in body weight during pharmacological treatment of depression. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 367-375.	2.1	41
102	Variation in GNB3 predicts response and adverse reactions to antidepressants. <i>Journal of Psychopharmacology</i> , 2011, 25, 867-874.	4.0	44
103	Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis. <i>Journal of Psychopharmacology</i> , 2011, 25, 675-684.	4.0	5
104	Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. <i>Psychological Medicine</i> , 2011, 41, 463-476.	4.5	102
105	Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. <i>Pharmacogenomics Journal</i> , 2011, 11, 138-145.	2.0	70
106	Pharmacogenetics of antidepressant response. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 101-125.	2.8	45
107	Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: Clinical description and the role of the 5-HTTLPR. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 528-538.	2.6	31
108	Early and Delayed Onset of Response to Antidepressants in Individual Trajectories of Change During Treatment of Major Depression. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1478-1484.	2.2	117



#	ARTICLE	IF	CITATIONS
109	Stress and Inflammation Reduce Brain-Derived Neurotrophic Factor Expression in First-Episode Psychosis. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1677-1684.	2.2	245
110	History of suicide attempts among patients with depression in the GENDEP project. <i>Journal of Affective Disorders</i> , 2010, 123, 131-137.	4.1	18
111	Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. <i>Journal of Affective Disorders</i> , 2010, 127, 337-342.	4.1	32
112	Clinical lessons from GENDEP for the treatment of depression. <i>Annals of General Psychiatry</i> , 2010, 9, .	2.7	0
113	Regional distribution of clomipramine and desmethylclomipramine in rat brain and peripheral organs on chronic clomipramine administration. <i>Journal of Psychopharmacology</i> , 2010, 24, 1261-1268.	4.0	15
114	Genome-Wide Association Study of Major Recurrent Depression in the U.K. Population. <i>American Journal of Psychiatry</i> , 2010, 167, 949-957.	7.2	221
115	Trajectories of change in depression severity during treatment with antidepressants. <i>Psychological Medicine</i> , 2010, 40, 1367-1377.	4.5	107
116	Letter to the Editor: Further evidence is required to confirm association between CACNA1C gene variants and bipolar affective disorder. <i>Psychological Medicine</i> , 2010, 40, 702-704.	4.5	1
117	Gender differences in antidepressant drug response. <i>International Review of Psychiatry</i> , 2010, 22, 485-500.	2.8	139
118	Housekeeping gene expression is affected by antidepressant treatment in a mouse fibroblast cell line. <i>Journal of Psychopharmacology</i> , 2010, 24, 1253-1259.	4.0	18
119	Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project. <i>American Journal of Psychiatry</i> , 2010, 167, 555-564.	7.2	314
120	Phospholipase A2 and Cyclooxygenase 2 Genes Influence the Risk of Interferon- $\gamma$ -Induced Depression by Regulating Polyunsaturated Fatty Acids Levels. <i>Biological Psychiatry</i> , 2010, 67, 550-557.	1.3	160
121	DOES STRESS CONTRIBUTE TO INFLAMMATORY AND METABOLIC ABNORMALITIES IN FIRST EPISODE PSYCHOSIS?. <i>Schizophrenia Research</i> , 2010, 117, 369-370.	2.0	0
122	The genetics of affective disorder and suicide. <i>European Psychiatry</i> , 2010, 25, 275-277.	0.2	55
123	Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment. <i>Schizophrenia Research</i> , 2010, 116, 234-242.	2.0	253
124	Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. <i>Schizophrenia Research</i> , 2010, 119, 75-78.	2.0	112
125	No association between genetic markers inBDNFgene and lithium prophylaxis in a Greek sample. <i>International Journal of Psychiatry in Clinical Practice</i> , 2010, 14, 154-157.	2.4	7
126	Disclosure of religious beliefs. <i>British Journal of Psychiatry</i> , 2009, 195, 368-368.	2.8	0



#	ARTICLE	IF	CITATIONS
127	Extracting a needle from a haystack: reanalysis of whole genome data reveals a readily translatable finding. <i>Psychological Medicine</i> , 2009, 39, 1231-1235.	4.5	18
128	A UK consensus on the administration of aripiprazole for the treatment of mania. <i>Journal of Psychopharmacology</i> , 2009, 23, 231-240.	4.0	21
129	Adverse reactions to antidepressants. <i>British Journal of Psychiatry</i> , 2009, 195, 202-210.	2.8	205
130	Moderation of antidepressant response by the serotonin transporter gene. <i>British Journal of Psychiatry</i> , 2009, 195, 30-38.	2.8	143
131	Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial. <i>BMC Medicine</i> , 2009, 7, 60.	5.5	43
132	Body weight as a predictor of antidepressant efficacy in the GENDEP project. <i>Journal of Affective Disorders</i> , 2009, 118, 147-154.	4.1	89
133	Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon- $\alpha$ and ribavirin treatment. <i>Molecular Psychiatry</i> , 2009, 14, 1095-1104.	7.9	214
134	Genetic predictors of response to antidepressants in the GENDEP project. <i>Pharmacogenomics Journal</i> , 2009, 9, 225-233.	2.0	188
135	Genetic Predictors of Increase in Suicidal Ideation During Antidepressant Treatment in the GENDEP Project. <i>Neuropsychopharmacology</i> , 2009, 34, 2517-2528.	5.4	105
136	Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. <i>British Journal of Psychiatry</i> , 2009, 194, 252-259.	2.8	170
137	Pharmacogenetics of antidepressant response. , 2009, , 299-314.		3
138	Routine evaluation in first episode psychosis services: feasibility and results from the MiData project. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2008, 43, 960-967.	3.1	49
139	Duration of Untreated Psychosis, Referral Route, and Age of Onset in an Early Intervention in Psychosis Service and a Local CAMHS. <i>Child and Adolescent Mental Health</i> , 2008, 13, 130-133.	3.5	15
140	Change in sexual dysfunction with aripiprazole: a switching or add-on study. <i>Journal of Psychopharmacology</i> , 2008, 22, 244-253.	4.0	75
141	Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. <i>Journal of Psychopharmacology</i> , 2008, 22, 323-329.	4.0	34
142	Measuring depression: comparison and integration of three scales in the GENDEP study. <i>Psychological Medicine</i> , 2008, 38, 289-300.	4.5	227
143	Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. <i>Journal of Psychopharmacology</i> , 2006, 20, 400-410.	4.0	96
144	TC2C USE OF CANNABIS IN A EAST-LONDON FIRST EPISODE PSYCHOSIS SAMPLE: DATA FROM THE GAP "GENETICS AND PSYCHOSIS" STUDY. <i>Schizophrenia Research</i> , 2006, 86, S26.	2.0	0

#	ARTICLE	IF	CITATIONS
145	0508 PATHWAYS TO CARE FOR TREATMENT OF YOUNG ADULTS WITH A PSYCHOTIC ILLNESS IN SOUTH LONDON. Schizophrenia Research, 2006, 86, S126.	2.0	1
146	0515 ARIPIPIRAZOLE SWITCHING STRATEGIES IN COMMUNITY PATIENTS WITH PSYCHOSIS. Schizophrenia Research, 2006, 86, S134.	2.0	1
147	Comments on "Prolactin Levels and Erectile Function in Patients Treated With Risperidone" (J Clin Tj ETQq1 1 0.784314 rgBT <sub>1</sub> /Overlo	1.4	1
148	Pharmacogenetics: antidepressant drug response. Psychiatry (Abingdon, England), 2005, 4, 30-34.	0.2	3
149	The genetics of depression and related traits. Current Psychiatry Reports, 2005, 7, 117-124.	4.5	21
150	Psychiatry and the "new genetics": hunting for genes for behaviour and drug response. British Journal of Psychiatry, 2005, 186, 91-92.	2.8	15
151	Comment on Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Current Medical Research and Opinion, 2004, 20, 1649-1649.	1.9	5
152	Clinical relevance of discoveries in psychopharmacogenetics. Advances in Psychiatric Treatment, 2004, 10, 455-465.	0.5	3
153	Early intervention in psychosis: from Government prescription to clinical practice. Psychiatric Bulletin, 2003, 27, 243-244.	0.3	2
154	Pharmacogenetics in the postgenomic era.. , 2003, , 335-361.		7
155	Clozapine response and genetic variation in neurotransmitter receptor targets. , 2002, , 217-244.		0
156	Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics and Genomics, 2000, 10, 43-48.	5.7	82
157	Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics and Genomics, 2000, 10, 695-704.	5.7	35
158	THE RELEVANCE OF ETHNIC INFLUENCES ON PHARMACOGENETICS TO THE TREATMENT OF PSYCHOSIS. Drug Metabolism and Drug Interactions, 2000, 16, 15-38.	0.3	27
159	Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice. Journal of Psychopharmacology, 2000, 14, 353-359.	4.0	39
160	The pharmaco-economics of atypical antipsychotics. International Journal of Psychiatry in Clinical Practice, 1999, 3, 237-248.	2.4	12
161	Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation. British Journal of Clinical Pharmacology, 1999, 48, 388-394.	2.4	34
162	Association analysis between dopamine receptor genes and bipolar affective disorder. Psychiatry Research, 1999, 86, 193-201.	3.3	51

#	ARTICLE	IF	CITATIONS
163	CYP2D6 polymorphisms in Alzheimer's disease, with and without extrapyramidal signs, showing no apolipoprotein E $\epsilon$ 4 effect modification. <i>Biological Psychiatry</i> , 1999, 45, 426-429.	1.3	19
164	Apolipoprotein E: Depressive illness, depressive symptoms, and Alzheimer's disease. <i>Biological Psychiatry</i> , 1998, 43, 159-164.	1.3	44
165	Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia. <i>Schizophrenia Research</i> , 1998, 32, 87-92.	2.0	39
166	Cost-effectiveness of clozapine. <i>British Journal of Psychiatry</i> , 1997, 171, 125-130.	2.8	86
167	Pharmacogenetic factors in treatment-resistant schizophrenia: The role of CYP2D6 variants. <i>Schizophrenia Research</i> , 1997, 24, 89.	2.0	0
168	Allelic variation of the 5-HT2C receptor in psychosis. <i>Schizophrenia Research</i> , 1997, 24, 90-91.	2.0	0
169	No evidence for an association of affective disorders with high- or low-activity allele of catechol-o-methyltransferase gene. <i>Biological Psychiatry</i> , 1997, 42, 282-285.	1.3	101
170	Allelic association between a ser-9-gly polymorphism in the D3 receptor gene and schizophrenia. <i>Schizophrenia Research</i> , 1996, 18, 163.	2.0	0
171	No Association between Parkinson's Disease and Low-Activity Alleles of Catechol-O-Methyltransferase. <i>Biochemical and Biophysical Research Communications</i> , 1996, 228, 780-784.	2.1	83
172	Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. <i>Human Genetics</i> , 1996, 97, 714-719.	3.8	141
173	The serotonin transporter is a potential susceptibility factor for bipolar affective disorder. <i>NeuroReport</i> , 1996, 7, 1675-1679.	1.2	190
174	Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. <i>Human Genetics</i> , 1996, 97, 714-719.	3.8	12
175	Cytochrome P4502D6 genotype does not determine response to clozapine.. <i>British Journal of Clinical Pharmacology</i> , 1995, 39, 417-420.	2.4	65
176	Homozygous osteogenesis imperfecta unlinked to collagen I genes. <i>Human Genetics</i> , 1988, 78, 233-236.	3.8	64
177	An RFLP close to the human collagen I gene COL1A1. <i>Nucleic Acids Research</i> , 1987, 15, 4699-4699.	14.5	11
178	Biological treatments: general considerations. , 0, , 567-585.		0